NCT04918732View on ClinicalTrials.gov

NAFLD Primary Care

NARecruitingINTERVENTIONAL
Enrollment

1,470

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Non-Alcoholic Fatty Liver DiseaseCardiovascular DiseasesType2 DiabetesMetabolic SyndromeOverweight and Obesity
Interventions
DIAGNOSTIC_TEST

FibroScan

The FibroScan device developed by Echosens (France) measures the liver stifness and steatosis based on a pulse of sound waves that goes through the liver.

Trial Locations (1)

Unknown

RECRUITING

Maastricht University, Maastricht

All Listed Sponsors
lead

Maastricht University

OTHER